Primary composite end point 2 : Time from randomization to first occurrence of a 3-part composite MACE, defined as CV death, non-fatal MI, or non-fatal stroke Key secondary end points 2 : Time from randomization to first occurrence of: Cardiovascular death All-cause death Other secondary end points 2 : Time from randomization to first occurrence of: Fatal or non-fatal myocardial infarction Fatal or non-fatal stroke Relevant supportive secondary end points 2 : Change in body weight from baseline to week 104 Change in waist circumference from baseline to week 104 Change in systolic blood pressure from baseline to week 104 Change in diastolic blood pressure from baseline to week 104 Change in heart rate from baseline to week 104 Change in A1c from baseline to week 104 Change in lipids from baseline to week 104 LDL, HDL, triglycerides, and total cholesterol
The calculator suite addresses every aspect of dose determination, from initial reconstitution through ongoing protocol adjustments
About 15 million children and teens in the United States are considered obese, a number that has tripled over the past three decades, according to the U.S
By simultaneously aiming at GLP-1, GIP, and glucagon receptors, these drugs, such as retatrutide, deliver significantly greater efficacy than current therapies, expanding the addressable patient base
Mounjaro enthlt den Wirkstoff Tirzepatid, der patentrechtlich durch das US-amerikanische Pharmaunternehmen Eli Lilly and Company geschtzt ist
nausea was the single most common complaint (14.1%), followed by diarrhea (4.7%)
